 Home > Medical News > Medical World News > The participation of new crown treatment drugs in the negotiation of the 2022 medical insurance drug catalog

The participation of new crown treatment drugs in the negotiation of the 2022 medical insurance drug catalog

 Last Update: 2023-02-02
 Source: Internet
 Author: User

Tags

new jersey america

linkedin new york office

famous drugs

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The negotiation of the 2022 national medical insurance drug catalogue officially ended
on January 8.
The person in charge of the Department of Pharmaceutical Administration of the National Medical Security Administration introduced the participation of new crown treatment drugs in the negotiation of the medical insurance drug catalog
.
This year, a total of three new crown treatment drugs, including azvudine tablets, nematevir tablets/ritonavir tablets combination packaging (hereinafter referred to as "Paxlovid"), and lung cleansing and detoxification granules, participated in the negotiations through the
procedures of self-declaration, formal review and expert review by enterprises.
Among them, the negotiation of azvudine tablets and lung cleansing and detoxification granules was successful, and Paxlovid was unsuccessful
due to the high quotation of the manufacturer Pfizer Investment Co.
, Ltd.
The person in charge said that although Paxlovid failed to be included in the medical insurance catalogue through negotiation, according to the "Notice on Optimizing the Relevant Policies for Medical Security for Patients with Novel Coronavirus Infection after the Implementation of "Class B and B Tube" jointly issued by the National Medical Insurance Administration and relevant departments" (hereinafter referred to as the "Notice"), all therapeutic drugs in the "Diagnosis and Treatment Plan for Novel Coronavirus Infection (Trial Version 10)", including Paxlovid, azvudine tablets, monoravir capsules, Cold and wet granules, etc.
, medical insurance will pay temporarily until March 31
, 2023.
During this period, insured patients with new coronavirus infection can enjoy medical insurance reimbursement policies for these drugs
.
In addition, after Azvudine tablets and lung cleansing detoxification granules were included in the national medical insurance drug list after this negotiation, there are more than 600 kinds of drugs in the national medical insurance drug list for the treatment of fever, cough and other new crown symptoms
.
At the same time, in order to meet the needs of the treatment of patients infected with new coronavirus infection in various places, local medical insurance departments have recently temporarily included a batch of new crown symptomatic treatment drugs into the payment scope
of local medical insurance in combination with the operation of local medical insurance funds.
In general, medical insurance reimburses a wide
range of drugs for the treatment of new coronavirus infection.
The person in charge also said that the Office of the National Health Insurance Administration recently issued the "Guidelines for the Formation of New Crown Treatment Drugs (Trial)", which adopts full-cycle and multi-level measures to guide enterprises to open, transparent and reasonable pricing
for newly marketed antiviral treatment drugs needed for the prevention and treatment of new coronavirus infection 。 In the next step, the National Health Insurance Administration will continue to adhere to the people-centered approach, implement the decision-making and deployment of the Party Central Committee and the State Council, make every effort to adjust the medical insurance drug list, include more new drugs and good drugs in the medical insurance drug list, effectively reduce the burden of medical treatment for the masses, and help solve the people's worries
about seeing a doctor.

={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)];

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.